EUSOMA position regarding breast implant associated anaplastic large cell lymphoma (BIA-ALCL) and the use of textured implants
| Autor: | Maria João Cardoso, Isabel T. Rubio, Lorenza Marotti, Marjut Leidenius, Giuseppe Curigliano, Lynda Wyld, B. Cutuli, Laura Biganzoli |
|---|---|
| Přispěvatelé: | II kirurgian klinikka, Department of Surgery, Clinicum, Department of Oncology, HUS Comprehensive Cancer Center |
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
Breast Implants 3122 Cancers Breast Neoplasms Prosthesis Design Risk Assessment Regulatory authority law.invention 03 medical and health sciences 0302 clinical medicine Postoperative Complications law 3123 Gynaecology and paediatrics Medicine Humans In patient BIA-ALCL 030212 general & internal medicine Anaplastic large-cell lymphoma Breast Implantation Risk reducing surgery Anaplastic large cell lymphoma Breast implant associated large cell lymphoma business.industry General surgery Mortality rate WOMEN General Medicine medicine.disease 3126 Surgery anesthesiology intensive care radiology ALCL 3. Good health Europe Textured implants 030220 oncology & carcinogenesis Breast implant Lymphoma Large-Cell Anaplastic Surgery Female Implant business Rare disease |
| Zdroj: | Breast (Edinburgh, Scotland). 44 |
| ISSN: | 1532-3080 |
| Popis: | Correction Volume: 48 Pages: 102-102 DOI: 10.1016/j.breast.2019.10.005 Published: DEC 2019 During the last two decades the number of breast implants used in aesthetic, oncologic and risk reducing surgery has increased substantially mainly due to the improvement and confirmed safety of these devices. Since identification of the first case of anaplastic large cell lymphoma associated with a breast implant (BIA-ALCL) 20 years ago, there has been an increase in the number of reports of this very rare disease, demonstrating a clear association with breast implants. Whilst the majority of cases are localised and cured by implant removal and full capsulectomy, a small percentage require chemotherapy and the mortality rate is very low. The evidence linking BIA-ALCL to implant surface texturing, as the majority of cases were diagnosed in patients with textured implants, has raised concerns about the long term safety of these devices resulting in patient and regulatory authority concerns globally. We hereby present the current published knowledge about the link between BIA-ALCL and implant surface texture and a review of current regulatory and professional body advice across Europe, which may enable a better understanding of this rare disease, how to manage and ultimately prevent it. We conclude by giving EUSOMA recommendation, towards the unnecessary change in attitudes towards implant based surgery, according to the most recent available published evidence as long as patients are properly informed about the risk of BIA-ALCL. (C) 2019 Elsevier Ltd. All rights reserved. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect